Showing results (11-20 of 15) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Urology|January 22, 2019
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled TrialHenry D Mitcheson, Suvajit Samanta, Karen Muldowney, et al.Journal of Neuroimmunology|August 16, 2008
Bladder dysfunction in mice with experimental autoimmune encephalomyelitisCengiz Z Altuntas, Firouz Daneshgari, Guiming Liu, et al.Current Medical Research and Opinion|June 29, 2012
Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III studyEugene R Viscusi, Tara L Frenkl, Craig T Hartrick, et al.European Urology Oncology|May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance StatusPetros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.Pageof 2